^
    1d
    SONIC: Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Fred Hutchinson Cancer Center | N=20 --> 30
    Enrollment change
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs) • sonrotoclax (BGB-11417) • Mabtas (rituximab biosimilar)
    3d
    68Ga-pentixafor PET/CT shows better diagnostic performance than 18F-FDG PET/CT in chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and review of literature. (PubMed, Front Oncol)
    Compared with 18F-FDG, 68Ga-pentixafor PET/CT detected more lesions with significantly higher tracer uptake. This case suggests that, for patients with CLL/SLL, 68Ga-pentixafor PET/CT demonstrates significantly superior performance in evaluating the tumor burden and delineating the disease extent compared with 18F-FDG PET/CT.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    3d
    Immune receptor translocation-associated protein 1 and myeloid nuclear differentiation antigen are useful markers for the differential diagnosis of marginal zone lymphoma. (PubMed, Pathology)
    Expression of IRTA1 alone, or either IRTA1+ or MNDA+, was less frequent among MZL with plasma cell differentiation than among MZL with classical cell morphology (p=0.063 and 0.071, respectively), albeit not significantly. IRTA1 and MNDA are sensitive and specific markers for the differential diagnosis of MZL, and they may be helpful in distinguishing MZL from histologic mimics.
    Journal
    |
    CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
    6d
    Primary Prostatic Alveolar Rhabdomyosarcoma in Adult, a Diagnostic Pitfall: Report of an Extremely Rare Tumor. (PubMed, Int J Surg Pathol)
    The treatment protocol and adjuvant drugs differ significantly from prostatic adenocarcinoma or small cell carcinoma, necessitating an accurate histological diagnosis for appropriate patient management. A molecular work-up can be useful in challenging specimens.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin) • MYOD1 (Myogenic Differentiation 1) • NKX3-1 (NK3 homeobox 1)
    6d
    A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P4, N=150, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Zydelig (idelalisib) • Jaypirca (pirtobrutinib)
    6d
    Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Jaypirca (pirtobrutinib)
    6d
    BGB-16673-102: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (clinicaltrials.gov)
    P1/2, N=146, Recruiting, BeiGene | Trial completion date: Sep 2027 --> Jan 2029 | Trial primary completion date: Feb 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    catadegbrutinib (BGB-16673)
    8d
    BGB-11417-303: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (clinicaltrials.gov)
    P3, N=630, Recruiting, BeOne Medicines
    Trial initiation date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • sonrotoclax (BGB-11417)
    9d
    STOP-CLL-DCT: Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P2 trial
    9d
    Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL (clinicaltrials.gov)
    P2, N=40, Recruiting, Massachusetts General Hospital | Trial completion date: Mar 2027 --> Mar 2029 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    10d
    Soundtrack-E: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=408, Recruiting, AstraZeneca | N=276 --> 408 | Trial completion date: Feb 2028 --> Jun 2029
    Enrollment change • Trial completion date
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisone • surovatamig (AZD0486)
    14d
    Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (clinicaltrials.gov)
    P2, N=61, Recruiting, University of Utah | Trial primary completion date: Jun 2026 --> Mar 2027
    Trial primary completion date